Since ibrutinib induces lymphocytosis, residual MCL cells in the blood could be cleared by alemtuzumab, as the anti-CD52 antibody is more active in blood than in lymph nodes and could help to yield MRD negativity [55]. Here, CD52 is linked to mantle cell lymphoma.